Plain-English translation of NCT04396873 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Parkinson's Disease research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
Researchers want to understand whether two inflammation markers called COX-1 and COX-2 are elevated in the brains of people with neurodegenerative diseases like Parkinson's, Alzheimer's, or ALS. This study uses a special type of brain imaging called PET scanning to measure these markers and compare them between people with these diseases and healthy volunteers. The goal is to learn whether measuring these markers could help doctors better understand and diagnose brain diseases in the future.
Currently, doctors don't have a reliable way to measure inflammation in the living brain as a sign of neurological disease. This research could open new doors for earlier diagnosis and better understanding of what's happening in the brains of people with these conditions.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will come to the National Institutes of Health (NIH) for brain imaging scans using a PET camera, which takes pictures of inflammation in your brain. Some participants may have two scanning sessions to test how reliable the measurements are. You'll also have blood tests and a heart test (EKG) to make sure it's safe for you to participate. The entire process typically takes several hours across one or more visits.
AI-generated summary from trial data ยท Jun 10, 2026 ยท Not medical advice
United States